TrialsgrambetaRCTs are beautiful

STELLAR

2023

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

In 323 patients with pulmonary arterial hypertension, sotatercept added to background therapy improved 6-minute walk distance compared with placebo.

Result

Primary endpoint: Change in 6-minute walk distance at 24 weeks

+40.8 m placebo-corrected; clinical worsening or death HR 0.16.

Original publication
Subtopic
Activin signalling
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Hoeper MM, et al. N Engl J Med. 2023;388(16):1478-1490.doi 10.1056/NEJMoa2213558

Discussion & critique

An activin-signalling inhibitor, a mechanism beyond vasodilators. Led to approval; ZENITH later showed a mortality-relevant benefit in high-risk PAH.

Discussed in podcasts